Management tracks: Grail, Celyad, Hua

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired.

Cell therapy company Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said CFO Patrick Jeanmart will step down, effective Sept. 3. He will be succeeded by Filippo Petti, who is VP of healthcare investment banking at Wells Fargo Securities LLC...